Stock Alerts
FONT-SIZE Plus   Neg

Halozyme Therapeutics Inc. (HALO) Climbed Sharply Following Upgrade

BMO Capital Markets upgraded its rating on shares of Halozyme Therapeutics Inc. (HALO: Quote) Monday to "Outperform" from "Market Perform."

Halozyme Therapeutics gapped up sharply Monday and climbed throughout the first 2 hours of trade. The stock finished up by 1.13 at $8.34 on above average volume and leaped to nearly a 4-month high.

Click here to receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback:

comments powered by Disqus